Nexus6 Steps Up its Global Presence with Three New Appointments
Auckland, New Zealand, September 6th 2013 – Nexus6 Ltd, a digital health company dedicated to improving respiratory care, today announced three appointments to its senior management team following the Company’s successful US$3.6m financing earlier in 2013.
Nexus6 is a global leader in the development and manufacturing of intelligent monitoring solutions that improve the management of COPD and asthma, called Smartinhaler™.
Smartinhaler™ provides real-time tracking of medication use and audio-visual reminders that have been clinically proven to significantly increase adherence to preventative medications.
Nexus6 is experiencing increased demand for its innovative products and services, and has grown its senior leadership team to extend the Company’s global reach and support its future growth plans.
Dr. Veronique Bouchet has joined as Vice President of Business Development for Europe, Christopher Stevens has been appointed as Chief Operating Officer, and Chris Mander has taken on the role of Head of Quality and Regulatory.
Based in London, UK, Dr. Veronique Bouchet will focus on Nexus6’s corporate strategy and drive business development activities in Europe. Veronique has extensive pharmaceutical industry experience and has held a variety of senior international roles across several therapeutic areas and functions, including drug development, business development, M&A, most recently with AstraZeneca. Dr. Bouchet is the founder of Novudel Associates, a life sciences consulting company. She is a non-executive director of International Biotechnology Trust PLC and of the Stevenage Bioscience Catalyst.
Christopher Stevens joins Nexus6 as Chief Operating Officer. Chris brings more than more 20 years experience in international product development for the North American, UK, and Australian markets. Prior to Nexus6 Chris was global Chief Technology officer for Orion Health, a leading health information technology company that provides clinical workflow and integration software to the global healthcare sector.
Chris Mander has been appointed as Nexus6’s new head of Regulatory and Quality, where he brings more than 20 years of experience from the respiratory medical device and patient monitoring sectors. Chris’s extensive knowledge of the North American, European, and Australasian product approvals and compliance processes brings solid support to Nexus6’s pipeline of innovation the Company is rolling out.
These hires follow the appointment of Dr Doug Wilson as Chairman to the Nexus6 Board in February 2013.
Dr. Wilson has decades of experience in the pharmaceutical industry, including global Head of Medicine and Regulatory Affairs at Boehringer Ingelheim.
“This calendar year Nexus6 has assembled a senior leadership team of highly focussed experts in the field of respiratory technology commercialisation” added Garth Sutherland, Chief Executive Officer. “The unique combination of skills and global experience will ensure that Nexus6 is well positioned for continuing international growth” he said.
-Ends-
For further information:
Nexus6 Ltd
Garth Sutherland, CEO
+64 21 653 344
Veronique Bouchet, VP Business Development Europe
+44 7803 079 374
For media enquiries:
College Hill
Sue Charles/Katherine Granger
+44 20 7866 7855
About Nexus6
Nexus6 Ltd is a world-leading digital technology company headquartered in Auckland, New Zealand.
Nexus6 provides digital health solutions for inhaled respiratory medications, called Smartinhaler™.
Smartinhaler comprises intelligent devices that track and remind respiratory medication use, and mobile applications that report inhaler usage patterns to a cloud based service platform in real time.
Smartinhaler has been proven to significantly improve patient adherence to preventative medications, resulting in improved outcomes for patients, increased medication utilisation for pharmaceutical companies, and healthcare cost savings for payors. For more information, please visithttp://www.smartinhaler.com/